Lorenzo Falchi MD; ASH 2025: Bispecific Antibody Epcoritamab Combination Beats Standard of Care for Patients with Relapsed/Refractory Follicular Lymphoma

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Armchair Anonymous: Bad Customer 54 min · 25 Sep 2026 · Armchair Expert with Dax Shepard

Headlines: Car crash kills junior police officer 4 min · 25 Sep 2026 · The Daily Aus

Day 268: Rebuilding the Temple (2026) 29 min · 25 Sep 2026 · The Bible in a Year (with Fr. Mike Schmitz)

NPR News: 09-25-2026 3AM EDT 5 min · 25 Sep 2026 · NPR News Now

ADHD Expert: Why You Feel Motivated But Can't Do Anything 1h 9m · 25 Sep 2026 · The Jefferson Fisher Podcast

3AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

Report any issue

Source

Recorded30 Jan 2026

Publisheraudiomedica.com ↗

Handlerec:19315684

Show notes

This episode discusses how the bispecific antibody Epcoritamab, in combination with rituximab and lenalidomide, has outperformed standard treatment for relapsed/refractory follicular lymphoma in the phase three epcore FL-1 trial. Dr. Lorenzo Falchi, an attending physician at Memorial Sloan Kettering, was interviewed at the ASH 2025 Annual Meeting, where these significant findings, including improved ORR and PFS, were presented, demonstrating a substantial reduction in the risk of progression or

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in